Want to see HK:6622 full AI Analyst Report?
6622 Stock Chart & Stats
HK$3.17
HK$0.01(0.78%)
At close: 4:00 PM EST
HK$3.17
HK$0.01(0.78%)
Day’s Range― - ―
52-Week RangeHK$2.38 - HK$4.60
Previous CloseN/A
Volume310.50K
Average Volume (3M)1.25M
Market Cap
HK$1.39B
Enterprise ValueHK$502.65
Total Cash (Recent Filing)HK$1.30B
Total Debt (Recent Filing)HK$292.48M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,749,000
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Bulls Say, Bears Say
Bulls Say
Supportive Balance SheetA relatively strong equity base and low leverage give Zhaoke financial flexibility to fund clinical development and commercialization without immediate refinancing. Over 2–6 months this reduces short-term solvency risk and supports execution of R&D and go-to-market plans despite operating losses.
Focused Ophthalmology FranchiseA concentrated strategy in ophthalmic therapeutics builds domain expertise and aligns R&D, regulatory and commercial efforts. This specialization supports durable competitive advantages in clinical development, approval pathways, and targeted commercial rollout versus unfocused peers.
Improving Cash Flow TrendAlthough still negative, the improvement in free cash flow signals initial progress in cost control or operational efficiency. If sustained, this trend can lengthen runway, reduce near-term funding needs and indicate management can progressively rein in cash burn over coming quarters.
Bears Say
Persistent Operating LossesLarge, ongoing operating losses indicate the business has not demonstrated scalable profitability. Over multiple quarters this erodes retained capital, increases reliance on external funding, and raises execution risk for continued clinical development and commercialization.
Sustained Cash BurnConsistent negative operating and free cash flow creates a structural funding need. Over 2–6 months, continued cash burn forces dilution or debt raises, constrains R&D and commercial investments, and limits the firm's ability to respond to competitive or regulatory hurdles.
Revenue InstabilityA sharp revenue decline and high negative growth indicate weak commercial traction or disrupted sales execution. Such instability undermines forecasting, delays path to scale, and magnifies the impact of fixed costs on margins, raising medium-term viability concerns.
Zhaoke Ophthalmology Ltd. News
6622 FAQ
What was Zhaoke Ophthalmology Ltd.’s price range in the past 12 months?
Zhaoke Ophthalmology Ltd. lowest stock price was HK$2.38 and its highest was HK$4.60 in the past 12 months.
What is Zhaoke Ophthalmology Ltd.’s market cap?
Zhaoke Ophthalmology Ltd.’s market cap is HK$1.39B.
When is Zhaoke Ophthalmology Ltd.’s upcoming earnings report date?
Zhaoke Ophthalmology Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 15 days.
How were Zhaoke Ophthalmology Ltd.’s earnings last quarter?
Zhaoke Ophthalmology Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.184 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Zhaoke Ophthalmology Ltd. overvalued?
According to Wall Street analysts Zhaoke Ophthalmology Ltd.’s price is currently Overvalued.
Does Zhaoke Ophthalmology Ltd. pay dividends?
Zhaoke Ophthalmology Ltd. does not currently pay dividends.
What is Zhaoke Ophthalmology Ltd.’s EPS estimate?
Zhaoke Ophthalmology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhaoke Ophthalmology Ltd. have?
Zhaoke Ophthalmology Ltd. has 548,749,000 shares outstanding.
What happened to Zhaoke Ophthalmology Ltd.’s price movement after its last earnings report?
Zhaoke Ophthalmology Ltd. reported an EPS of -HK$0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.614%.
Which hedge fund is a major shareholder of Zhaoke Ophthalmology Ltd.?
Currently, no hedge funds are holding shares in HK:6622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhaoke Ophthalmology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.72%
Trailing 12-Months
Company Description
Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.